Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FNTA | P49354 | 3/20 | 0.49 |
| ▸ | FNTB | P49356 | 3/20 | 0.49 |
| ▸ | PGGT1B | P53609 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14408750 | 1.00 | FNTA (0.49) | FNTAFNTBPGGT1B | |
| SCHEMBL16079895 | 0.98 | FNTA (0.51) | FNTAFNTBPGGT1B | |
| SCHEMBL16079891 | 0.98 | FNTA (0.51) | FNTAFNTBPGGT1B | |
| SCHEMBL16079903 | 0.83 | FNTA (0.54) | FNTAFNTB | |
| SCHEMBL16079884 | 0.83 | FNTA (0.54) | FNTAFNTB | |
| SCHEMBL15888102 | 0.82 | FNTA (0.44) | FNTAFNTBPGGT1B | |
| SCHEMBL9130707 | 0.82 | FNTA (0.48) | FNTAFNTBPGGT1B | |
| SCHEMBL16079909 | 0.81 | FNTA (0.47) | FNTAFNTBPGGT1B | |
| SCHEMBL9127713 | 0.81 | FNTA (0.50) | FNTAFNTBPGGT1B | |
| SCHEMBL16079907 | 0.80 | FNTA (0.49) | FNTAFNTBPGGT1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9416149-B2 | Methods to modulate Rac1 import and to treat pulmonary fibrosis | UNIVERSITY OF IOWA RESEARCH FOUNDATION (US) | 2016-08-16 | — | — | US | claimed |
| EP-2988753-A1 | METHODS TO MODULATE RAC1 IMPORT AND TO TREAT PULMONARY FIBROSIS | University of Iowa Research Foundation (US) | 2016-03-02 | — | — | EP | claimed |
| US-20150005261-A1 | METHODS TO MODULATE RAC1 IMPORT AND TO TREAT PULMONARY FIBROSIS | UNIVERSITY OF IOWA RESEARCH FOUNDATION (US) | 2015-01-01 | — | — | US | claimed |
| WO-2014176546-A1 | METHODS TO MODULATE RAC1 IMPORT AND TO TREAT PULMONARY FIBROSIS | UNIVERSITY OF IOWA RESEARCH FOUNDATION (US) | 2014-10-30 | — | — | WO | claimed |
| US-7268124-B2 | Geranylgeranyl pyrophosphate synthase inhibitors | UNIVERSITY OF IOWA RESEARCH FOUNDATION (US) | 2007-09-11 | — | — | US | claimed |
| EP-1793832-B1 | GERANYLGERANYL PYROPHOSPHATE SYNTHASE INHIBITORS | UNIV IOWA RES (US) | 2014-07-23 | — | — | EP | disclosed |
| US-7268124-B2 | Geranylgeranyl pyrophosphate synthase inhibitors | UNIVERSITY OF IOWA RESEARCH FOUNDATION (US) | 2007-09-11 | — | — | US | disclosed |
| EP-1793832-A2 | GERANYLGERANYL PYROPHOSPHATE SYNTHASE INHIBITORS | University of Iowa Research (US) | 2007-06-13 | — | — | EP | disclosed |
| US-20060052347-A1 | Geranylgeranyl pyrophosphate synthase inhibitors | UNIVERSITY OF IOWA RESEARCH FOUNDATION | 2006-03-09 | — | — | US | disclosed |
| WO-2006026380-A2 | GERANYLGERANYL PYROPHOSPHATE SYNTHASE INHIBITORS | UNIVERSITY OF IOWA RESEARCH FOUNDATION (US) | 2006-03-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150005261-A1 | METHODS TO MODULATE RAC1 IMPORT AND TO TREAT PULMONARY FIBROSIS | RHOT2, RHOA, RAC1 | FNTA 521/4885FNTB 223/4885PGGT1B 1337/4885 |
| US-20060052347-A1 | Geranylgeranyl pyrophosphate synthase inhibitors | GGPS1, FDPS, COASY | FNTA 4/4885FNTB 5/4885PGGT1B 17/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.